January 1, 2014
View Archives Issues
It is indeed ironic that 16 years after the landmark Burris study, innovations in pancreatic cancer treatment still lack essential quality-of-life data.
Change in CA19-9 after the First Cycle of second-line Pancreatic Cancer Treatment Predicts PFS and OSHopefully, as multi-institution, randomized trials are developed for second-line treatment of pancreatic cancer, CA19-9 levels will be included both pre- and post-first cycle treatment and responses compared with the established RECIST criteria.
Identification of Prognostic Factors for Early Mortality in Treatment of Metastatic Colorectal CancerCalculating 60-day mortality risk by these readily available parameters (ECOG PS and WBC) can be used to identify high-risk patients who may require heightened surveillance after standard or experimental chemotherapy or, alternatively, a reduction in treatment intensity.
This paper represents the largest collection of cases with central path review and provides better clarity to prognostic factors previously intimated from retrospective work.